SOFAR SPA
SOFAR SPA Patent applications | ||
Patent application number | Title | Published |
---|---|---|
20130142880 | BECLOMETHASONE DIPROPIONATE COMPOSITIONS IN MODIFIED-RELEASE GASTRO-RESISTANT MICROSPHERES AND PROCESS FOR OBTAINING THEM - The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions. | 06-06-2013 |
20130079399 | NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES - The present invention refers to the compounds corresponding to the following general formula (I): | 03-28-2013 |
20130030571 | ROBOTIZED SURGERY SYSTEM WITH IMPROVED CONTROL - A robotized surgery system ( | 01-31-2013 |
20120141592 | CONTROLLED-RELEASE GRANULAR COMPOSITIONS CONTAINING MESALAZINE AND PROCESS FOR THE MANUFACTURE THEREOF - The present invention refers to controlled release granular compositions of mesalazine and their use in the treatment of inflammatory pathologies of the intestinal tract. The aforesaid granular compositions comprise: a) a central core comprising an inert substrate; b) an intermediate layer comprising mesalazine and one or more physiologically acceptable excipients; c) a gastro-resistant coating. The present invention then refers to a process for obtaining the aforesaid granular compositions. | 06-07-2012 |
20100261174 | Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis - A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the β-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the β-catenin signalling pathway, such as μ-protocadherin, E-cadherin, β-catenin, Axin1, ICAT, p21 | 10-14-2010 |